Skip to Main Content
BLACK FRIDAY SALE

60% off Quiver Premium for new subscribers

...

Use Promo Code:

BLACKFRIDAY26
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Insmed gains after takeover report adds to momentum from strong recent execution

None

Insmed Incorporated (INSM) is up 16.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst was a report that Sanofi is evaluating a potential acquisition of Insmed, which would naturally push shares higher on takeover expectations. The move was likely amplified by Insmed’s already strong commercial momentum, including rapid BRINSUPRI growth, higher 2026 product guidance, and continuing pipeline progress.

Details:

  • A report circulating on November 19 said Sanofi has been speaking with advisers while weighing a possible bid for Insmed, putting M&A speculation at the center of the rally.
  • The stock’s sharp advance was strong enough to trigger a temporary volatility halt, showing that traders quickly repriced the company for a possible deal premium.
  • In late October, Insmed posted third-quarter 2026 revenue of $524.4 million, including $400.1 million from BRINSUPRI and $124.4 million from ARIKAYCE, while also raising 2026 guidance for both products.
  • Insmed also highlighted regulatory and pipeline progress, including FDA priority review for an ARIKAYCE label expansion and ongoing Phase 3 development work for TPIP, which may have made the company more attractive strategically.
  • Sources:

    Bloomberg, Insmed, Reuters

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $INSM Insider Trading Activity

    INSM Insider Trades

    $INSM insiders have traded $INSM stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.

    Here’s a breakdown of recent trading of $INSM stock by insiders over the last 6 months:

    • ROGER ADSETT (Chief Operating Officer) has made 0 purchases and 2 sales selling 242,220 shares for an estimated $32,207,189.
    • MARTINA M.D. FLAMMER (Chief Medical Officer) has made 0 purchases and 6 sales selling 43,899 shares for an estimated $5,303,018.
    • WILLIAM LEWIS (Chair and CEO) has made 0 purchases and 7 sales selling 35,519 shares for an estimated $3,781,343.
    • DAVID R BRENNAN sold 25,000 shares for an estimated $3,100,000
    • MICHAEL ALEXANDER SMITH (Chief Legal Officer) has made 0 purchases and 3 sales selling 10,114 shares for an estimated $1,060,833.
    • MELVIN MD SHAROKY sold 5,000 shares for an estimated $637,650
    • SARA BONSTEIN (Chief Financial Officer) sold 2,404 shares for an estimated $245,857

    To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    EARLY ACCESS
    Receive INSM Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $INSM Hedge Fund Activity

    We have seen 400 institutional investors add shares of $INSM stock to their portfolio, and 411 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $INSM Congressional Stock Trading

    Members of Congress have traded $INSM stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

    Here’s a breakdown of recent trading of $INSM stock by members of Congress over the last 6 months:

    To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

    $INSM Analyst Ratings

    Wall Street analysts have issued reports on $INSM in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • HC Wainwright & Co. issued a "Buy" rating on 11/04/2026
    • Guggenheim issued a "Buy" rating on 11/02/2026
    • Morgan Stanley issued a "Overweight" rating on 10/21/2026
    • Barclays issued a "Overweight" rating on 09/30/2026
    • Goldman Sachs issued a "Buy" rating on 09/24/2026
    • Roth Capital issued a "Buy" rating on 09/15/2026
    • JP Morgan issued a "Overweight" rating on 08/10/2026

    To track analyst ratings and price targets for $INSM, check out Quiver Quantitative's $INSM forecast page.

    $INSM Price Targets

    Multiple analysts have issued price targets for $INSM recently. We have seen 13 analysts offer price targets for $INSM in the last 6 months, with a median target of $195.0.

    Here are some recent targets:

    • Matthew Caufield from HC Wainwright & Co. set a target price of $220.0 on 11/04/2026
    • Vamil Divan from Guggenheim set a target price of $201.0 on 11/02/2026
    • Matthew Harrison from Morgan Stanley set a target price of $213.0 on 10/21/2026
    • Eliana Merle from Barclays set a target price of $207.0 on 09/30/2026
    • Andrea Newkirk from Goldman Sachs set a target price of $188.0 on 09/24/2026
    • Adam Walsh from Roth Capital set a target price of $198.0 on 09/15/2026
    • Jessica Fye from JP Morgan set a target price of $175.0 on 08/10/2026

    This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Add Quiver Quantitative to your preferred sources on Google Google News Logo

    Suggested Articles